Kintegral Advisory LLC Has $4.47 Million Holdings in Zoetis Inc. (NYSE:ZTS)

Kintegral Advisory LLC decreased its position in shares of Zoetis Inc. (NYSE:ZTS) by 4.5% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 27,459 shares of the company’s stock after selling 1,279 shares during the period. Kintegral Advisory LLC’s holdings in Zoetis were worth $4,474,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Hancock Whitney Corp lifted its position in shares of Zoetis by 0.3% in the third quarter. Hancock Whitney Corp now owns 18,569 shares of the company’s stock worth $3,628,000 after purchasing an additional 61 shares in the last quarter. Strategy Asset Managers LLC lifted its position in Zoetis by 3.5% during the 3rd quarter. Strategy Asset Managers LLC now owns 1,822 shares of the company’s stock worth $356,000 after buying an additional 62 shares in the last quarter. VeraBank N.A. lifted its position in Zoetis by 4.1% during the 4th quarter. VeraBank N.A. now owns 1,562 shares of the company’s stock worth $254,000 after buying an additional 62 shares in the last quarter. Procyon Advisors LLC boosted its stake in shares of Zoetis by 1.4% during the 4th quarter. Procyon Advisors LLC now owns 4,712 shares of the company’s stock worth $768,000 after buying an additional 63 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators grew its holdings in shares of Zoetis by 6.6% in the 4th quarter. Deseret Mutual Benefit Administrators now owns 1,045 shares of the company’s stock valued at $170,000 after acquiring an additional 65 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Up 1.9 %

Shares of ZTS opened at $160.39 on Friday. The firm’s 50-day simple moving average is $166.51 and its 200 day simple moving average is $178.04. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The firm has a market cap of $71.82 billion, a P/E ratio of 29.32, a price-to-earnings-growth ratio of 2.78 and a beta of 0.90. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.53.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating the consensus estimate of $1.37 by $0.03. The company had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. On average, analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.25%. The ex-dividend date is Monday, April 21st. Zoetis’s dividend payout ratio is currently 36.56%.

Insider Activity

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the sale, the executive vice president now owns 16,107 shares in the company, valued at $2,757,196.26. The trade was a 1.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is currently owned by company insiders.

Analyst Ratings Changes

ZTS has been the topic of several analyst reports. Stifel Nicolaus dropped their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Leerink Partners assumed coverage on Zoetis in a research note on Monday, December 2nd. They set an “outperform” rating and a $215.00 price objective on the stock. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Piper Sandler dropped their price target on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a research report on Monday, February 10th. Finally, Barclays lifted their price objective on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $214.90.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.